Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Biegstraaten M, Cox TM, Belmatoug N, et al. Blood Cells Mol Dis. 2018;68:203-208.

 

Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher disease.

Hollak CE, Aerts JM, Belmatoug N, et al. Blood Cells Mol Dis. 2010;44(2):86-7.

 

Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.

Hollak CE1, vom Dahl S, Aerts JM, et al. Blood Cells Mol Dis. 2010;44(1):41-7.

 

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Cox TM, Aerts JM, Andria G, et al. J Inherit Metab Dis. 2003;26(6):513-26.

 

Management of neuronopathic Gaucher disease: a European consensus.

Vellodi A, Bembi B, de Villemeur et al. J Inherit Metab Dis. 2001 Jun;24(3):319-27.

EWGGD Code of Practice with Industry

EWGGD Working Group Policy

EWGGD Statement on Home Therapy

Send us your recent published research to be shared with our community and to help us to be updated on the scientific progresses in Gaucher disease